Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Fibronectin type III domain containing protein | 0.002 | 0.0212 | 0.0091 |
Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0018 | 0.0122 | 0.0122 |
Echinococcus granulosus | roundabout 2 | 0.002 | 0.0212 | 0.0212 |
Echinococcus multilocularis | tyrosine protein kinase | 0.0249 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.002 | 0.0212 | 0.0091 |
Schistosoma mansoni | cell adhesion molecule | 0.002 | 0.0212 | 1 |
Echinococcus granulosus | tyrosine protein kinase | 0.0249 | 1 | 1 |
Echinococcus multilocularis | roundabout 2 | 0.002 | 0.0212 | 0.0212 |
Loa Loa (eye worm) | TK protein kinase | 0.0249 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.0212 | 0.0212 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.0212 | 0.0212 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.0212 | 0.0212 |
Loa Loa (eye worm) | hypothetical protein | 0.0246 | 0.9878 | 0.9878 |
Brugia malayi | Immunoglobulin I-set domain containing protein | 0.002 | 0.0212 | 0.0091 |
Schistosoma mansoni | nephrin | 0.002 | 0.0212 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
(functional) | = 0.5429007954 ug/ml | In vitro cytotoxicity evaluation on human fibroblasts measured by fluorescence after 72h | WHO/TDR. | No reference |
% motility reduction (functional) | = 33.4 % | Motility reduction assay in Onchocerca lienalis microfilariae | WHO/TDR. | No reference |
% motility reduction (functional) | = 58.3 % | Motility reduction assay in Schistosoma mansoni Egyptian sambon adult worms | WHO/TDR. | No reference |
IC50 (functional) | = 0.404 ug/ml | In vitro activity against Trypanosoma cruzi in human lung fibroblast measured by colorimetry after 7 days | WHO/TDR. | No reference |
IC50 (functional) | = 0.404 ug/ml | WHO-TDR: Chagas disease | ChEMBL. | No reference |
IC50 | = 0.542900795 ug/ml | WHO-TDR: Cytotoxicity | ChEMBL. | No reference |
IC50 (functional) | = 1.180920012 ug/ml | WHO-TDR: Malaria | ChEMBL. | No reference |
IC50 (functional) | = 1.1809200123 ug/ml | In vitro activity against Plasmodium falciparum measured by colorimetry after 72h | WHO/TDR. | No reference |
IC50 (functional) | = 4.312 ug/ml | In vitro activity against Trypanosoma brucei measured by florescence after 24h | WHO/TDR. | No reference |
IC50 (functional) | = 4.312 ug/ml | WHO-TDR: Human African Trypanosomiasis (HAT) | ChEMBL. | No reference |
IC50 (functional) | > 13.637 ug/ml | In vitro activity against Leishmania infantum in mouse macrophages measured by cell viability after 5 days | WHO/TDR. | No reference |
IC50 (functional) | > 13.637 ug/ml | WHO-TDR: Leishmaniasis | ChEMBL. | No reference |
Inhibition (functional) | = 58.3 % | WHO-TDR: Schistosomiasis | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Trypanosoma brucei gambiense | |||
Homo sapiens | ChEMBL23 | ||
Leishmania infantum | ChEMBL23 | ||
Trypanosoma cruzi | ChEMBL23 | ||
Plasmodium falciparum |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.